EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of In Vitro Parkinson's Disease Model Mediated by MPP + and α‐Synuclein Using Wharton's Jelly Mesenchymal Stem Cells

Naisarg Gamit iD, Manasi Patil iD, B S Soumya iD, Arun Dharmarajan iD, Sudha Warrier iD

CNS Neuroscience & Therapeutics · 2025

DOI: 10.1111/cns.70299 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2025. Verfasst von Naisarg Gamit und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Stem Cells and Cardiovascular Regeneration, Manipal Institute of Regenerative Medicine, Manipal Academy of Higher Education (MAHE)…. Hauptthemen laut MEDLINE: Mesenchymal Stem Cells, alpha-Synuclein, Wharton Jelly, 1-Methyl-4-phenylpyridinium. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Engineering Research Board, Department of Health Research, India.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Main Problem The mechanism behind Parkinson's disease (PD) is still unclear, and a cure to stop its progression is yet to be found. This is mainly due to the lack of effective human PD models. To address this, we generated an in vitro PD model using Wharton's jelly‐derived mesenchymal stem cells (WJMSCs).

Methods

WJMSCs were isolated from the umbilical cord using an enzymatic method. MSCs were characterized by RT‐PCR, immunofluorescence, and trilineage differentiation. MSCs were differentiated into dopaminergic neuron‐like cells (DAN) and further degenerated by treating them with either MPP+ iodide or the A53T mutated α‐synuclein variant. Gene expression analysis by qRT‐PCR and protein analysis by immunofluorescence, flow cytometry, and ELISA were performed. Assays to measure LDH, ROS, NO, GSH, and mitochondrial membrane potential were also performed after degeneration.

Results

WJMSCs were positive for MSC markers and were able to differentiate into adipocytes, chondrocytes, and osteocytes. DAN obtained after the differentiation of WJMSCs for 48 h expressed neuronal markers such as synapsin 1, neuropilin, neurofilament, and MAPT along with dopaminergic markers such as Nurr1, DAT, TH, DDC, and KCNJ6 and were functionally active. Upon degeneration of DAN by MPP+ or A53T, elevated levels of SNCA and downregulation of TH, Nurr1, DAT, and KCNJ6 were observed. Furthermore, increased expression of α‐SYN was detected at the protein level as well. Finally, reduction in mitochondrial membrane potential and GSH levels along with an increase in intracellular ROS, nitrite production, and LDH levels confirmed that the in vitro PD‐like model exhibited the molecular characteristics of PD.

Conclusion

This model is rapid, cost‐efficient, and effective for understanding the molecular mechanisms of the disease and can also be used for screening of emerging therapeutics for PD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mesenchymal Stem Cellsalpha-SynucleinWharton Jelly1-Methyl-4-phenylpyridiniumParkinson DiseaseHumansCell DifferentiationDopaminergic NeuronsCells, Cultured

Stichwörter der Autor:innen

A53TMPP+Parkinson's diseaseROSWJMSCsmesenchymal stem cellsnitriteα‐Synuclein

Substanzen

alpha-Synuclein1-Methyl-4-phenylpyridinium

Autor:innen und Institutionen

  • Division of Cancer Stem Cells and Cardiovascular Regeneration, Manipal Institute of Regenerative Medicine, Manipal Academy of Higher Education (MAHE), Bangalore, India.
  • School of Human Sciences, The University of Western Australia, Nedlands, Western Australia, Australia.
  • Curtin Medical School, Curtin University, Perth, Western Australia, Australia.
  • Department of Biotechnology, Faculty of Biomedical Sciences and Technology, Sri Ramachandra Institute of Higher Education and Research, Chennai, India.

ORCID-Profile: Naisarg Gamit, Manasi Patil, B S Soumya, Arun Dharmarajan, Sudha Warrier

Förderung

  • Science and Engineering Research Board
  • Department of Health Research, India

Zitieren

APA

Gamit, N., Patil, M., Soumya, B. S., Dharmarajan, A., & Warrier, S. (2025). Development of In Vitro Parkinson's Disease Model Mediated by MPP + and α‐Synuclein Using Wharton's Jelly Mesenchymal Stem Cells. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.70299

Vancouver

Gamit N, Patil M, Soumya BS, Dharmarajan A, Warrier S. Development of In Vitro Parkinson's Disease Model Mediated by MPP + and α‐Synuclein Using Wharton's Jelly Mesenchymal Stem Cells. CNS Neuroscience & Therapeutics. 2025. doi:10.1111/cns.70299

BibTeX
@article{Gamit2025,
  author = {Gamit, Naisarg and Patil, Manasi and Soumya, B S and Dharmarajan, Arun and Warrier, Sudha},
  title = {Development of In Vitro Parkinson's Disease Model Mediated by MPP + and α‐Synuclein Using Wharton's Jelly Mesenchymal Stem Cells},
  journal = {CNS Neuroscience & Therapeutics},
  year = {2025},
  doi = {10.1111/cns.70299}
}
Kostenlos starten →